The treatment of relapsed multiple myeloma is based in part on the degree previous exposure and resistance to commonly used drug classes. For patients with a first relapse, an anti-CD38 antibody–based combination preferred unless have already received these agents, which case carfilzomib-based option can be excellent choice. more refractory disease, bispecific antibody emerging choice, but CAR ...